CJC-1295 vs Ipamorelin: What They Are, How They Differ, and What People Notice

CJC-1295 vs Ipamorelin: What They Are, How They Differ, and What People Notice Compare CJC-1295 vs ipamorelin in plain English: what each is, how GH signaling differs, what effects people look for, and the biggest tradeoffs. CJC-1295 and Ipamorelin are the two most commonly paired growth hormone peptides. CJC-1295 is a GHRH analog that amplifies growth hormone releasing hormone signaling, while Ipamorelin is a selective ghrelin-receptor agonist. They work through complementary pathways and are frequently stacked to enhance pulsatile growth hormone release. Type GHRH analog (modified GRF 1-29) GH secretagogue (ghrelin receptor agonist) Primary research area Growth hormone amplification Growth hormone release Key mechanism GHRH receptor agonism, GH pulse amplification Ghrelin/GHS-R1a receptor agonism Half-life ~30 min (no DAC) or ~8 days (with DAC) ~2 hours Common pairing Stacked with Ipamorelin Stacked with CJC-1295 CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH with modifications to resist enzymatic degradation. It comes in two forms: without DAC (also called Mod GRF 1-29) with a 30-minute half-life, and with DAC (Drug Affinity Complex) extending the half-life to approximately 8 days. Read the full CJC-1295 guide → Ipamorelin is a selective pentapeptide growth hormone secretagogue that stimulates GH release by activating the ghrelin receptor (GHS-R1a). Unlike other GH secretagogues such as GHRP-6, ipamorelin is considered highly selective — it stimulates GH release without significantly affecting cortisol, prolactin, or appetite in preclinical and early clinical studies. Read the full Ipamorelin guide → CJC-1295 binds the GHRH receptor on pituitary somatotrophs and amplifies the natural GH release pulse. It does not initiate a new GH pulse on its own — it increases the amplitude of existing pulses. The DAC version binds albumin for extended circulation, providing sustained GHRH receptor stimulation over days rather than minutes. Ipamorelin activates the ghrelin receptor (GHS-R1a) to initiate growth hormone release from the pituitary. Unlike GHRP-6 or GHRP-2, it shows minimal cross-reactivity with other hormone pathways. This selectivity means it stimulates a clean GH pulse without significant increases in cortisol, aldosterone, or prolactin in research models. GH release Amplifies existing GH pulses via GHRH-R Initiates GH pulses via ghrelin receptor Sleep quality May enhance deep sleep via GH elevation Associated with improved sleep in anecdotal reports Body composition Indirect via sustained GH/IGF-1 elevation Indirect via pulsatile GH release Recovery Supports repair through IGF-1 pathway Supports repair through GH-mediated mechanisms IGF-1 elevation Sustained IGF-1 increase (especially with DAC) Transient IGF-1 elevation per dose CJC-1295 and Ipamorelin are the most commonly stacked growth hormone peptides in research protocols. They appear together because they activate two different arms of the GH axis — CJC-1295 amplifies the GHRH signal while Ipamorelin initiates a pulse through the ghrelin receptor. This dual-pathway approach mimics the body's natural GH control system more closely than either peptide alone. The combination is theorized to produce larger and more physiological GH pulses while maintaining the selectivity that makes Ipamorelin attractive over older secretagogues like GHRP-6. Researchers compare them to understand whether one alone is sufficient or whether the combination provides meaningful synergy for GH output, IGF-1 elevation, and downstream effects on body composition and recovery. CJC-1295 Dosage Calculator Ipamorelin Dosage Calculator Peptide Reconstitution Calculator Growth Hormone Stack (CJC-1295 + Ipamorelin) BPC-157 vs TB-500 BPC-157 vs GHK-Cu CJC-1295 is a GHRH analog that amplifies existing growth hormone pulses through the GHRH receptor. Ipamorelin is a ghrelin receptor agonist that initiates new GH pulses. They act on two different receptors in the pituitary, which is why they are typically stacked together. They activate complementary arms of the GH axis. CJC-1295 amplifies the hormone-releasing signal while Ipamorelin triggers the pulse. Together they may produce larger, more physiological GH output than either peptide alone, mimicking the natural dual-signal control system more closely. Individually, Ipamorelin typically produces a more acute GH spike, while CJC-1295 (especially with DAC) provides sustained GH elevation over a longer period. The combination is studied because acute pulses plus sustained amplification may yield the most robust overall GH and IGF-1 response. Ipamorelin is considered the most selective GH secretagogue, with minimal effects on cortisol, prolactin, or appetite. CJC-1295 without DAC is also well-tolerated in research. The DAC version may cause more sustained effects due to its extended half-life of approximately 8 days. CJC-1295 Peptide Guide Ipamorelin Peptide Guide Peptide Half-Life Chart The PeptideUniv app includes the full reconstitution calculator, dosing schedules, cycle tracker, and reminders — all in one place. For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional before making any medical or health-related decisions.